{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:06:59Z","timestamp":1791922019837,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.autrev.2018.04.007","type":"journal-article","created":{"date-parts":[[2018,8,11]],"date-time":"2018-08-11T19:50:18Z","timestamp":1534017018000},"page":"1022-1027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Does cyclophosphamide still play a role in glomerular diseases?"],"prefix":"10.1016","volume":"17","author":[{"given":"Claudio","family":"Ponticelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Escoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.04.007_bb0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00003088-198712030-00002","article-title":"Pharmacokinetics of anticancer drugs in children","volume":"12","author":"Crom","year":"1987","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.autrev.2018.04.007_bb0010","first-page":"4e974393","article-title":"Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent","volume":"20","author":"Kanakry","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.autrev.2018.04.007_bb0015","first-page":"100","article-title":"Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2018.04.007_bb0020","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3899\/jrheum.150065","article-title":"Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases","volume":"42","author":"Yilmaz","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2018.04.007_bb0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s004670000523","article-title":"A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children","volume":"16","author":"Latta","year":"2001","journal-title":"Pediatr. Nephrol."},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2018.04.007_bb0030","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2012","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.autrev.2018.04.007_bb0035","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8","article-title":"Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer","volume":"39","author":"Koyama","year":"1977","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.autrev.2018.04.007_bb0040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2215\/CJN.05000516","article-title":"Minimal change disease","volume":"12","author":"Vivarelli","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.autrev.2018.04.007_bb0045","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1681\/ASN.2012070734","article-title":"The treatment of minimal change disease in adults","volume":"24","author":"Hogan","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.autrev.2018.04.007_bb0050","article-title":"Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children","author":"Pravitsitthikul","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.autrev.2018.04.007_bb0055","first-page":"1326","article-title":"Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial","volume":"8","author":"Ponticelli","year":"1993","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.autrev.2018.04.007_bb0060","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.ajkd.2007.02.270","article-title":"Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome","volume":"49","author":"Kyrieleis","year":"2007","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"10.1016\/j.autrev.2018.04.007_bb0065","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00467-011-1830-0","article-title":"Cyclophosphamide in steroid-dependent nephrotic syndrome","volume":"26","author":"Azib","year":"2011","journal-title":"Pediatr. Nephrol."},{"issue":"12","key":"10.1016\/j.autrev.2018.04.007_bb0070","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00467-012-2234-5","article-title":"Is cyclophosphamide effective in patients with IgM-positive minimal change disease?","volume":"27","author":"Geier","year":"2012","journal-title":"Pediatr. Nephrol."},{"issue":"6","key":"10.1016\/j.autrev.2018.04.007_bb0075","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/BF02093714","article-title":"The treatment of minimal change nephrotic syndrome: lessons learned from multicentre co-operative studies","volume":"150","author":"Brodehl","year":"1991","journal-title":"Eur. J. Pediatr."},{"issue":"6","key":"10.1016\/j.autrev.2018.04.007_bb0080","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ki.1986.130","article-title":"Adult-onset minimal change nephrotic syndrome: a long-term follow-up","volume":"29","author":"Nolasco","year":"1986","journal-title":"Kidney Int."},{"issue":"11","key":"10.1016\/j.autrev.2018.04.007_bb0085","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1093\/oxfordjournals.ndt.a027136","article-title":"Long-term outcome of adult-onset minimal-change nephropathy","volume":"11","author":"Mak","year":"1996","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.autrev.2018.04.007_bb0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.ajkd.2013.12.002","article-title":"Canadian society of nephrology commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis: management of nephrotic syndrome in children","volume":"63","author":"Samuel","year":"2014","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.autrev.2018.04.007_bb0095","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF01956754","article-title":"Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie","volume":"152","author":"Ehrich","year":"1993","journal-title":"Eur. J. Pediatr."},{"issue":"2","key":"10.1016\/j.autrev.2018.04.007_bb0100","first-page":"53","article-title":"The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study","volume":"36","author":"Banfi","year":"1991","journal-title":"Clin. Nephrol."},{"issue":"2","key":"10.1016\/j.autrev.2018.04.007_bb0105","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/0971-4065.53321","article-title":"Ponticelli regimen in idiopathic nephrotic syndrome","volume":"19","author":"Das","year":"2009","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.autrev.2018.04.007_bb0110","doi-asserted-by":"crossref","first-page":"941831","DOI":"10.1155\/2013\/941831","article-title":"Urinary IgG and \u03b12-macroglobulin are powerful predictors of outcome and responsiveness to steroids and cyclophosphamide in idiopathic focal segmental glomerulosclerosis with nephrotic syndrome","volume":"2013","author":"Bazzi","year":"2013","journal-title":"Biomed. Res. Int."},{"issue":"1","key":"10.1016\/j.autrev.2018.04.007_bb0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.autrev.2018.04.007_bb0120","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/0272-6386(95)90568-5","article-title":"A review of therapeutic studies of idiopathic membranous glomerulopathy","volume":"25","author":"Hogan","year":"1995","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"10.1016\/j.autrev.2018.04.007_bb0125","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1994","journal-title":"Kidney Int."},{"issue":"3","key":"10.1016\/j.autrev.2018.04.007_bb0130","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.autrev.2018.04.007_bb0135","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.autrev.2018.04.007_bb0140","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/j.ajkd.2005.08.020","article-title":"Idiopathic membranous nephropathy: outline and rationale of a treatment strategy","volume":"46","author":"du Buf-Vereijken","year":"2005","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"10.1016\/j.autrev.2018.04.007_bb0145","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"van den Brand","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.autrev.2018.04.007_bb0150","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/ajkd.2001.27689","article-title":"Predicting progression in IgA nephropathy","volume":"38","author":"Bartosik","year":"2001","journal-title":"Am. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.autrev.2018.04.007_bb0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","article-title":"Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial","volume":"15","author":"Pozzi","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"issue":"23","key":"10.1016\/j.autrev.2018.04.007_bb0160","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"STOP-IgAN investigators, Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.autrev.2018.04.007_bb0165","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2018.04.007_bb0170","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy","volume":"13","author":"Ballardie","year":"2002","journal-title":"J Am Soc Neprol"},{"issue":"2","key":"10.1016\/j.autrev.2018.04.007_bb0175","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5414\/CP201887","article-title":"Treatment of severe IgA nephropathy: mycophenolate mofetil\/prednisone compared to cyclophosphamide\/prednisone","volume":"52","author":"Liu","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.autrev.2018.04.007_bb0180","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating primary, genetic, and secondary FSGS in adults: a Clinicopathologic approach","volume":"29","author":"De Vriese","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.autrev.2018.04.007_bb0185","doi-asserted-by":"crossref","unstructured":"J.C. Jennette, R.J. Falck, P.A. Bacon, N. Basu, M.C. Cid., F. Ferrario, L.F. Flores-Suarez, W.L. Gross, L. Guillevin, E.C. Hagen, G.S. Hoffman, D.R. Jayne, C.G. Kallenberg, P. Lamprecht, C.A. Langford, R.A. Luqmani, A.D. Mahr, E.L. Matteson, P.A. Merkel, S. Ozen, C.D. Pusey, N. Rasmussen, A.J. Rees, D.G. Scott, U. Specks, J.H. Stone, K. Takahashi, R.A. Watts, 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides, Arthritis Rheum. 65 (2013) 1\u201311.","DOI":"10.1002\/art.37715"},{"issue":"7","key":"10.1016\/j.autrev.2018.04.007_bb0190","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.autrev.2014.02.007","article-title":"Rapidly progressive crescentic glomerulonephritis: early treatment is a must","volume":"13","author":"Moroni","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.04.007_bb0195","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-150-10-200905190-00004","article-title":"EUVAS (European Vasculitis study group), pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"150","author":"de Groot","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.autrev.2018.04.007_bb0200","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"EUVAS investigators, pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.04.007_bb0205","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"European Vasculitis study group, Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.autrev.2018.04.007_bb0210","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"European Vasculitis Society (EUVAS), rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.04.007_bb0215","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"RAVE-ITN Research Group, Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.autrev.2018.04.007_bb0220","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1136\/ard.2011.153890","article-title":"ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process","volume":"70","author":"Holden","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.autrev.2018.04.007_bb0225","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.autrev.2018.04.007_bb0230","first-page":"614","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"III Austin","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.autrev.2018.04.007_bb0235","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/art.10142","article-title":"Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies","volume":"46","author":"Illei","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.04.007_bb0240","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis, the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.04.007_bb0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.autrev.2018.04.007_bb0250","first-page":"9","article-title":"Induction and maintenance therapy in proliferative lupus nephritis","volume":"23","author":"Ponticelli","year":"2010","journal-title":"J Nephrol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T22:46:45Z","timestamp":1661726805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218301794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1568997218301794"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.04.007","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does cyclophosphamide still play a role in glomerular diseases?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}